Company intelligence / Profile preview

Weikang Bio-Technology Group

Harbin, Heilongjiang, China

Ownership: Private
Development stage: Other

Overview

Weikang has developed and commercialized a range of TCM, generic pharmaceuticals, and health supplements, including several SFDA-approved (now NMPA) therapeutics for digestive, cardiovascular, immune, and age-related disorders. Notably, its ranitidine hydrochloride capsule (a generic of Zantac) was included on the Chinese National Drug Reimbursement List.

Therapeutic areas: ImmunologyInfectious DiseasesGastroenterologyCardiovascularOtherNeurologyWomen's Health
Modalities: Small moleculePlant extractTraditional medicineProtein
Industry: Biotech

Drug pipeline

1 asset

Weikang

Preclinical

Beyond the preview

Go deeper on Weikang Bio-Technology Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Weikang Bio-Technology Group.

Explore the full profile